Regeneron Pharmaceuticals, Inc. (REGN)
NASDAQ: REGN · Real-Time Price · USD
731.71
-3.10 (-0.42%)
Oct 2, 2026, 11:56 AM EDT - Market open
Regeneron Pharmaceuticals Ratios and Metrics
Market cap in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 2, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 73,065 | 79,193 | 76,639 | 93,403 | 77,057 | 66,029 | |
Market Cap Growth | 22.61% | 3.33% | -17.95% | 21.21% | 16.70% | 29.49% |
Enterprise Value | 57,949 | 63,170 | 61,056 | 80,414 | 66,767 | 57,309 |
Last Close Price | 734.81 | 768.90 | 705.67 | 870.08 | 714.75 | 625.62 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 2, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 18.17 | 17.58 | 17.37 | 23.63 | 17.76 | 8.18 |
Forward PE | 12.02 | 17.11 | 15.19 | 19.36 | 17.29 | 11.00 |
PS Ratio | 4.79 | 5.52 | 5.40 | 7.12 | 6.33 | 4.11 |
PB Ratio | 2.32 | 2.53 | 2.61 | 3.60 | 3.40 | 3.52 |
P/TBV Ratio | 2.45 | 2.64 | 2.72 | 3.75 | 3.54 | 3.52 |
P/FCF Ratio | 19.78 | 19.41 | 20.91 | 24.10 | 17.42 | 10.11 |
P/OCF Ratio | 15.89 | 15.91 | 17.34 | 20.33 | 15.37 | 9.32 |
PEG Ratio | 1.00 | 2.93 | 0.95 | 4.75 | 5.86 | 5.17 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 2, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 3.81 | 4.40 | 4.30 | 6.13 | 5.49 | 3.57 |
EV/EBITDA Ratio | 12.60 | 14.88 | 13.19 | 17.28 | 12.51 | 6.18 |
EV/EBIT Ratio | 14.19 | 17.06 | 14.73 | 19.00 | 13.37 | 6.37 |
EV/FCF Ratio | 15.76 | 15.48 | 16.66 | 20.75 | 15.09 | 8.78 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 2, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.09 | 0.10 | 0.10 | 0.11 | 0.12 | 0.14 |
Debt / EBITDA Ratio | 0.57 | 0.69 | 0.63 | 0.60 | 0.52 | 0.29 |
Debt / FCF Ratio | 0.72 | 0.73 | 0.80 | 0.72 | 0.63 | 0.41 |
Net Debt / Equity Ratio | -0.48 | -0.51 | -0.51 | -0.52 | -0.51 | -0.52 |
Net Debt / EBITDA Ratio | -3.21 | -3.74 | -3.23 | -2.89 | -2.17 | -1.06 |
Net Debt / FCF Ratio | -4.02 | -3.89 | -4.09 | -3.47 | -2.61 | -1.51 |
Asset Turnover | 0.39 | 0.37 | 0.40 | 0.42 | 0.45 | 0.76 |
Inventory Turnover | 2.74 | 2.53 | 2.51 | 2.51 | 2.37 | 2.74 |
Quick Ratio | 2.63 | 3.28 | 3.86 | 4.82 | 4.16 | 2.98 |
Current Ratio | 3.34 | 4.13 | 4.73 | 5.69 | 5.06 | 3.56 |
Return on Equity (ROE) | 14.04% | 14.87% | 15.95% | 16.26% | 20.94% | 54.21% |
Return on Assets (ROA) | 6.53% | 5.91% | 7.31% | 8.49% | 11.42% | 26.39% |
Return on Invested Capital (ROIC) | 13.50% | 13.04% | 18.58% | 22.38% | 26.65% | 60.13% |
Return on Capital Employed (ROCE) | 11.50% | 10.20% | 12.30% | 14.30% | 19.20% | 41.80% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 2, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 5.82% | 5.69% | 5.76% | 4.23% | 5.63% | 12.23% |
FCF Yield | 5.06% | 5.15% | 4.78% | 4.15% | 5.74% | 9.89% |
Dividend Yield | 0.51% | 0.46% | - | - | - | - |
Payout Ratio | 9.15% | 8.22% | - | - | - | - |
Buyback Yield / Dilution | 4.76% | 5.65% | -1.23% | -0.18% | -1.16% | 2.52% |
Total Shareholder Return | 5.26% | 6.11% | -1.23% | -0.18% | -1.16% | 2.52% |